Differentiation of herpes simplex virus types 1 and 2 by sensitivity to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
AUTOR(ES)
Mayo, D R
RESUMO
Selective inhibition of herpes simplex virus (HSV) type 1 replication but not of HSV type 2 replication by (E)-5-(2-bromovinyl)2'-deoxyuridine (BVDU) was utilized to differentiate clinical isolates of these viruses. BVDU (0.7 microgram/ml) reduced HSV type 1 PFU by an average of 2.74 log10, but had no effect on the plaque-forming ability of HSV type 2 isolates. The incorporation of BVDU into the media of primary cell cultures used for virus isolation in the clinical laboratory allowed for the correct presumptive identification of HSV types.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=272176Documentos Relacionados
- Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on synthesis of herpes simplex virus type 1-specific polypeptides.
- On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine.
- Metabolic fate of (E)-5-(2-bromovinyl)-2'-deoxyuridine in herpes simplex virus- and mock-infected cells.
- Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice.
- (E)-5-(2-bromovinyl)-2'-Deoxyuridine in the treatment of experimental herpes simplex keratitis.